

## MiSeq™ i100 Series


## Powerful, fast, and simple sequencing for oncology research

Access meaningful insights for all your oncology research by identifying key mutations, such as gene fusions, copy number alterations, and other genomic aberrations that underlie tumorigenesis.

The MiSeq i100 Series is here.



Gain more genomic insights and discovery power than you ever thought possible



## Rapidly uncover insights in your lab

Using the MiSeq i100 Series is as easy as...

1

## Simple, intuitive setup

Expedite setup with room-temperature, no-thaw consumables, and three step sample loading in under 20 minutes.

2

## Efficient workflow

Sample-to-analysis workflow means less hands-on time and simplified data analysis, which helps reduce the need for bioinformatics expertise.

3

## Accurate, fast results

Industry-standard accuracy ready when you are: obtain results quickly with ~4-15.5 hour run times.

Designed for efficient lab operations with reliable results




Intuitive interface for easy navigation



Easy onboarding for new users and applications



Maximized walk-away time throughout the workflow—saving time, resources, and money



The MiSeq i100 Series brings a new level of flexibility to labs of all sizes

## More applications enable more possibilities

With multiple reagent kits available, supporting a wide range of throughputs, labs can cost-effectively process samples at any scale.

Flow cell options:<sup>1</sup>

5M

→ 266

Myeloproliferative neoplastic samples for rapid profiling of driver genes<sup>2</sup>



25M

→ 20

Solid tumors characterized for DNA and RNA variants<sup>3</sup>

50M

→ 22

Myeloid cancer samples characterized<sup>4</sup>

100M

→ 6

Liquid biopsy samples profiled for cfDNA variants (Core LBx)<sup>5</sup>


Achieve high-quality data faster than ever

Powered by XLEAP-SBS™ chemistry, our fastest, highest-quality chemistry, sequencing run times are as fast as four hours. And with onboard secondary analysis, results can be generated in a single day.



## Improved run times

Runs as fast as four hours<sup>6</sup>



## Accurate, efficient analysis

Onboard DRAGEN™ software and access to a full suite of cloud-based analysis apps

## Sample-to-analysis workflow solutions

Oncology focused workflows are available and include library preparation kits, panels, sequencing on the MiSeq i100 Series, and preconfigured DRAGEN secondary analysis.


Streamline experimental planning with preselected library prep kits and targeted gene panels

Simplify data analysis with access to preconfigured pipelines, helping reduce need for bioinformatics expertise

Increase confidence in your results with access to data sets in BaseSpace Sequence Hub



Now labs of all sizes can bring proven sequencing in house



## Increased accessibility for improved outputs

Sequence confidently with global support services



97%

customer satisfaction score<sup>8</sup>

Learn how the MiSeq i100 Series from Illumina enables oncology research to gain insights and answers with unbelievable speed and accuracy.

What will you discover next?

[illumina.com/MiSeqi100](http://illumina.com/MiSeqi100)


## Sample-to-analysis workflow solutions

Oncology focused workflows are available and include library preparation kits, panels, sequencing on the MiSeq i100 Series, and preconfigured DRAGEN secondary analysis.


Streamline experimental planning with preselected library prep kits and targeted gene panels

Simplify data analysis with access to preconfigured pipelines, helping reduce need for bioinformatics expertise


Increase confidence in your results with access to data sets in BaseSpace Sequence Hub




Room-temperature shipping and storage



XLEAP-SBS reagents help deliver remarkable sustainability and user experience benefits




No dry ice, no cold packs, and no freezer storage required



85% reduction in packaging materials<sup>6</sup> and easy disposal for most parts



Simple setup and quick access from shelf storage optimizes uptime with no thawing required



"Now it can save time unpacking and save on waste. And it helps planning for the sequencing runs because we don't have to think two days before getting a kit out of the freezer. To think room-temperature storage really is a game-changer."

Geneviève Dompierre, Team Leader, NGS Sequencing, Genome Québec

High-quality sequencing, approachable NGS for

every lab, everywhere

Your trusted partner in genomics

10K+

MiSeq Systems installed

160K+

MiSeq Systems publications<sup>7</sup>

150+

Countries served

600+

Global experts

Sequence confidently with global support services



Regional teams offer local access with in-country, multilingual customer service



Technical assistance is available to help with instrument setup and experimental support



Worldwide peer network delivers additional support and insights



Broad training options available online and in person to support your experimental needs

Bring more possibilities to your lab

Learn how the MiSeq i100 Series from Illumina enables

oncology research to gain insights and answers

with unbelievable speed and accuracy.

What will you discover next?

[illumina.com/MiSeqi100](http://illumina.com/MiSeqi100)

For Research Use Only. Not for use in diagnostic procedures.

For Research Use Only. Not for use in diagnostic procedures.

© 2025 Illumina, Inc. All rights reserved. All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see [www.illumina.com/company/legal.html](http://www.illumina.com/company/legal.html).

<sup>1</sup> Based on 28K reads (2 × 150 bp) with an average of 100x coverage. Optimal sample parameters should be determined empirically.

<sup>2</sup> Based on 2.3M paired end reads per sample using Pillar® oncoReveal™ Myeloid Cancer CNV + RNA fusion panel

<sup>3</sup> As compared on 3.5M paired end reads per sample using Pillar® oncoReveal™ Myeloid Cancer CNV + RNA fusion panel

<sup>4</sup> Data calculations on file, Illumina, Inc. 2022

<sup>5</sup> Based on transactional surveys from technical support, service, and field application

<sup>6</sup> Based on transactional surveys from technical support, service, and field application

<sup>7</sup> Based on transactional surveys from technical support, service, and field application

<sup>8</sup> Based on transactional surveys from technical support, service, and field application

<sup>9</sup> Based on transactional surveys from technical support, service, and field application

<sup>10</sup> Based on transactional surveys from technical support, service, and field application

<sup>11</sup> Based on transactional surveys from technical support, service, and field application

<sup>12</sup> Based on transactional surveys from technical support, service, and field application

<sup>13</sup> Based on transactional surveys from technical support, service, and field application

<sup>14</sup> Based on transactional surveys from technical support, service, and field application

<sup>15</sup> Based on transactional surveys from technical support, service, and field application

<sup>16</sup> Based on transactional surveys from technical support, service, and field application

<sup>17</sup> Based on transactional surveys from technical support, service, and field application

<sup>18</sup> Based on transactional surveys from technical support, service, and field application

<sup>19</sup> Based on transactional surveys from technical support, service, and field application

<sup>20</sup> Based on transactional surveys from technical support, service, and field application

<sup>21</sup> Based on transactional surveys from technical support, service, and field application

<sup>22</sup> Based on transactional surveys from technical support, service, and field application

<sup>23</sup> Based on transactional surveys from technical support, service, and field application

<sup>24</sup> Based on transactional surveys from technical support, service, and field application

<sup>25</sup> Based on transactional surveys from technical support, service, and field application

<sup>26</sup> Based on transactional surveys from technical support, service, and field application

<sup>27</sup> Based on transactional surveys from technical support, service, and field application

<sup>28</sup> Based on transactional surveys from technical support, service, and field application

<sup>29</sup> Based on transactional surveys from technical support, service, and field application

<sup>30</sup> Based on transactional surveys from technical support, service, and field application

<sup>31</sup> Based on transactional surveys from technical support, service, and field application

<sup>32</sup> Based on transactional surveys from technical support, service, and field application

<sup>33</sup> Based on transactional surveys from technical support, service, and field application

<sup>34</sup> Based on transactional surveys from technical support, service, and field application

<sup>35</sup> Based on transactional surveys from technical support, service, and field application

<sup>36</sup> Based on transactional surveys from technical support, service, and field application

<sup>37</sup> Based on transactional surveys from technical support, service, and field application

<sup>38</sup> Based on transactional surveys from technical support, service, and field application

<sup>39</sup> Based on transactional surveys from technical support, service, and field application

<sup>40</sup> Based on transactional surveys from technical support, service, and field application

<sup>41</sup> Based on transactional surveys from technical support, service, and field application

<sup>42</sup> Based on transactional surveys from technical support, service, and field application

<sup>43</sup> Based on transactional surveys from technical support, service, and field application